[Therapeutic effects of chemotherapeutic regimen with pirarubicin for adult high-risk acute leukemia].

Abstract

OBJECTIVE:

To evaluate the therapeutic effects of chemotherapeutic regimen with pirarubicin in the management of adult high-risk acute leukemia.

METHODS:

Twenty-nine high-risk acute leukemia patients were selected as the treatment group and another 29 patients with similar pretreatment conditions as the control group. In the treatment group, 18 patients had acute non-lymphocytic leukemia (ANLL), and 8 had acute lymphocytic leukemia (ALL) and 3 had mixed leukemia, all received treatment regimens with pirarubicin+cytarabine, vincristine+pirarubicin+prednisone, Vincristine+pirarubicin+L-asparaginase (L)+prednisone or pirarubicin+cytarabine+vincristine+prednisone. Routine therapeutic regimens were adopted in the management of the control.

RESULTS:

In ANLL patients, the overall remission rate was significantly higher in the treatment group than in the control group (77.78% vs 44.44%, P=0.031). Patients in the treatment group had greater marrow suppression and higher incidence of infections than the control group (P=0.012).

CONCLUSION:

Regimens with pirarubicin is more effective than the routine regimens in the management of patients with high-risk ANLL and produce greater but tolerable marrow suppression.

• Authors: Fen Huang, Fan-yi Meng, Bing Xue, Xiao-li Liu, Yu Zhang, Chang-xiong Ye, Xian Zhang
• Journal: Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA (Di Yi Jun Yi Da Xue Xue Bao) Vol. 24 Issue 7 Pg. 768-70 (Jul 2004) ISSN: 1000-2588 [Print] China
• PMID: 15257898 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Doxorubicin
• pirarubicin

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Doxorubicin (administration & dosage, analogs & derivatives)
• Female
• Humans
• Leukemia, Myeloid, Acute (drug therapy)
• Male
• Middle Aged
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)